And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans. In fact, we have a lot of daydreaming to do, since we will be off for several days. Our agenda is rather modest, but hopefully satisfying. We plan to spend time with Mrs. Pharmalot and some Pharmalittles, catch up on our endless reading list, sponsor a listening party or two, observe some ancient rituals, and check in on a few long-lost family and friends. And what about you? This is a splendid opportunity to reacquaint yourself with people who matter, indulge your favorite pastimes, or simply plan the rest of your life. Well, whatever you do, have a grand time. But be safe. Enjoy, and see you next year.

The National Academies of Sciences, Engineering, and Medicine outlined a framework for prescribers and others to develop their own plans for acute pain, without offering any direct recommendations itself, STAT explains. The report says any group drafting prescribing guidelines should consider a host of factors: evidence, or lack thereof, for using opioids versus alternatives for a condition or procedure; downstream effects of any prescription, such as refill requests or unused pills; and potential implications on pain relief, quality of life, and harm.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • The last item adds a new winner though – the lawyers? It will mean grooming “the patent thickets” for biologics sooner and wider?

Comments are closed.

Sign up to receive a free weekly opinions recap from our community of experts.
Privacy Policy